Alumis’ (ALMS) Buy Rating Reaffirmed at Chardan Capital

Chardan Capital reissued their buy rating on shares of Alumis (NASDAQ:ALMS) in a research note released on Monday morning,Benzinga reports. The brokerage currently has a $38.00 target price on the stock.

A number of other research firms have also commented on ALMS. Loop Capital set a $37.00 price target on shares of Alumis in a research report on Wednesday, January 21st. Stifel Nicolaus assumed coverage on shares of Alumis in a report on Wednesday, February 25th. They set a “buy” rating and a $44.00 target price on the stock. Morgan Stanley boosted their price target on Alumis from $33.00 to $38.00 and gave the company an “overweight” rating in a research note on Friday, March 20th. Leerink Partners increased their price target on Alumis from $20.00 to $32.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 6th. Finally, Wells Fargo & Company lifted their price objective on Alumis from $17.00 to $39.00 and gave the company an “overweight” rating in a report on Tuesday, January 6th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $38.60.

Alumis Stock Down 18.5%

Shares of ALMS stock opened at $20.21 on Monday. Alumis has a 12-month low of $2.76 and a 12-month high of $30.60. The company has a market capitalization of $2.57 billion, a PE ratio of -6.60 and a beta of -2.16. The firm has a 50 day moving average price of $26.50 and a two-hundred day moving average price of $14.67.

Alumis (NASDAQ:ALMS) last announced its earnings results on Thursday, March 19th. The company reported ($0.95) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.05). Alumis had a negative return on equity of 116.97% and a negative net margin of 1,011.75%.The firm had revenue of $1.93 million for the quarter, compared to the consensus estimate of $2.75 million. As a group, research analysts expect that Alumis will post -8.51 EPS for the current year.

Insiders Place Their Bets

In other Alumis news, major shareholder Foresite Labs, Llc acquired 411,764 shares of the company’s stock in a transaction that occurred on Thursday, January 8th. The stock was acquired at an average cost of $17.00 per share, for a total transaction of $6,999,988.00. Following the transaction, the insider directly owned 5,702,536 shares in the company, valued at $96,943,112. This represents a 7.78% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, Director James B. Tananbaum bought 411,764 shares of the firm’s stock in a transaction on Thursday, January 8th. The stock was acquired at an average price of $17.00 per share, for a total transaction of $6,999,988.00. Following the transaction, the director owned 5,702,536 shares of the company’s stock, valued at approximately $96,943,112. The trade was a 7.78% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought 1,823,527 shares of company stock valued at $30,999,959 over the last ninety days. Company insiders own 40.70% of the company’s stock.

Institutional Investors Weigh In On Alumis

Several hedge funds and other institutional investors have recently made changes to their positions in ALMS. Ieq Capital LLC raised its stake in shares of Alumis by 4.1% during the fourth quarter. Ieq Capital LLC now owns 17,421 shares of the company’s stock valued at $170,000 after acquiring an additional 690 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in Alumis by 26.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,724 shares of the company’s stock valued at $46,000 after purchasing an additional 979 shares during the period. ProShare Advisors LLC raised its position in Alumis by 12.4% during the 4th quarter. ProShare Advisors LLC now owns 14,627 shares of the company’s stock worth $143,000 after purchasing an additional 1,618 shares during the last quarter. Stoneridge Investment Partners LLC lifted its holdings in Alumis by 8.1% during the 3rd quarter. Stoneridge Investment Partners LLC now owns 29,535 shares of the company’s stock worth $118,000 after buying an additional 2,210 shares during the period. Finally, Rhumbline Advisers grew its position in shares of Alumis by 21.7% in the 1st quarter. Rhumbline Advisers now owns 16,543 shares of the company’s stock valued at $102,000 after buying an additional 2,949 shares during the last quarter.

Key Alumis News

Here are the key news stories impacting Alumis this week:

• Positive Sentiment: Oppenheimer raised its price target to $55 and kept an “outperform” rating, signaling strong upside from current levels and giving investors a bullish institutional vote of confidence. Oppenheimer raises PT to $55 (Benzinga)
• Positive Sentiment: Morgan Stanley (coverage noted on TipRanks) maintained a Buy rating with a $38 target, citing strong Phase 3 data for Envu and an attractive risk/reward ahead of a planned 2026 FDA submission — a near‑term clinical/regulatory catalyst. Morgan Stanley maintains Buy (TipRanks)
• Positive Sentiment: Chardan Capital reaffirmed a “buy” rating with a $38 target, reinforcing analyst conviction around the clinical story and longer‑term upside. Chardan reaffirms Buy (Benzinga)
• Neutral Sentiment: HC Wainwright trimmed its target from $40 to $25 but left a “buy” rating intact — a mixed signal (reduced upside but continued positive view). HC Wainwright lowers PT to $25 (Benzinga)
• Negative Sentiment: Intraday selling is being attributed to investors locking in gains after roughly a 239% annual rise; technical commentary notes the stock tested/broke short‑term support levels, amplifying the drop. Why Is Alumis Stock Falling Monday? (Benzinga)
• Negative Sentiment: Fundamental pressures remain — recent quarter missed revenue and EPS expectations and the company shows deeply negative margins and ROE — which can make pullbacks sharper and raise the bar for sustained rallies. (Background: Q1 results and metrics)

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.